Expert Panel on Immune Globulin Product Supply and Related Impacts in Canada: Meeting #3

Meeting #3: Monday October 23, 2017 Time: 10:00-16:00 EDT

Jeanne Mance Building, 200 Eglantine Drive, Ottawa (Room #1203A)

Teleconference: 1-877-413-4785; Conference ID#: 5525434#

Meeting Objectives:

  1. Open dialogue with key stakeholders
  2. Review patient and advocacy positions
  3. Discuss evidence gathered to date
Participants
Panel Members Secretariat Observers
  • Dr. Penny Ballem (Chair)
  • Dr. Francine Décary
  • Dr. Patrick Robert (Special Advisor)
  • Dr. Merlyn Sayers (Special Advisor)
  • Dr. Marie-Anik Gagné
  • Connie Berry
  • Dr. Vicky Hogan
  • Dr. Chris Gravel
  • Robyn Cummings
  • Stacey Spicer
  • Kyle Norrie for Liz-Anne Gillham-Eisen, Director, HPFB
  • Abby Hoffman, Assistant Deputy Minister [Oct 23: for part only]
  • [various presenters as noted below]

Item

Welcome and introductions

Dr. Ballem reviewed the meeting objectives, and summarized the stakeholder outreach activities already undertaken and planned.

1. Approval of Agenda

Decision: The Panel endorsed the meeting agenda.

2. Endorsement of Record of Decisions of September 12, 2017 meeting

3. Discussion

Panel members discussed their observations and questions arising from the written submissions, and potential lines of inquiry related to the presentations to follow.  Questions about the current regulatory framework were addressed.  Dr. Décary explained that Héma-Québec was unable to provide some of the requested data because the Québec structure intentionally separates roles and responsibilities across different institutions.

Action:

Guest presentations and discussions (See attachment #3)

4. Canadian Blood Services presentation

Dr. Graham Sher, Jean-Paul Bédard, and Mathias Haun presented on behalf of Canadian Blood Services (CBS). They responded to questions from Panel members on a number of points, resulting in exchanges of views on:

Actions:

5. Héma-Québec presentation

Dr. Marc Germain presented on behalf of Héma-Québec (H-Q). He responded to questions from Panel members on a number of points, resulting in exchanges of views on:

6. Canadian Plasma Resources presentation

Dr. Barzin Bahardoust and Jim Pimblett presented on behalf of Canadian Plasma Resources (CPR). They responded to questions from Panel members on a number of points, resulting in exchanges of views on

7. Open discussion on the day's presentations and discussions

Panel members discussed key points from the presentations heard that will inform the Panel’s findings on supply and demand factors, relevant global and domestic contextual issues, cost and efficiency considerations, the role of the regulatory framework, and the relative urgency and likelihood of risks occurring.

Action:

8. Adjourned – day # 1.

Meeting #3 - resumed: Tuesday October 24, 2017 Time: 09:00-14:00 EDT

Jeanne Mance Building, 200 Eglantine Drive, Ottawa (Room #1301D)

1. Overnight thoughts or observations

The Chair led a discussion in regard to the emerging vision for the layout and high level content of the report; the need for graphics to ease communication of complex issues was identified.

2. Summary of Statements Submitted from Patient and Stakeholder Groups

Panel members discussed the submissions received from patient and stakeholder groups and the approach to the roundtable teleconferences scheduled for October 27 and 31, 2017.

3. Discussion

Panel members discussed the mini-reports prepared by the secretariat.  The Panel determined that in some areas sufficient foundation to frame their opinions had been provided, while additional information was requested on some topics.  Discussion was also held on topics emerging from other meeting discussions and materials, including:

Action:

Guest presentations and discussions

4. Therapure Biopharma Inc. presentation

Blaine Forshage and Mark Krause presented on behalf of Therapure.  They responded to questions from Panel members on a number of points, resulting in exchanges of views on:

After the Therapure presenters left, the Panel discussion included comment on challenges of managing a ‘hybrid’ (both blood and plasma) donor pool, such as information technology and inventory management issues.

Action:

5. Prometic presentation

Bill Bees presented on behalf of Prometic.  He responded to questions from Panel members on a number of points, resulting in exchanges of views on:

After the final presenters left, the Panel held an extended discussion to summarize and synthesize its views of and conclusions about the written and oral submissions received.  Key factors and findings were identified and a draft logic flow for the report was developed. The draft will evolve as further evidence is received.

Action:

6. Updates

N/A

7. Roundtable

N/A

8. Next meeting: December 7 & 8 in Ottawa

Confirmed

9. Adjournment

Page details

Date modified: